These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 7687707)
61. Characterization of ORG 20241, a combined phosphodiesterase IV/III cyclic nucleotide phosphodiesterase inhibitor for asthma. Nicholson CD; Shahid M; Bruin J; Barron E; Spiers I; de Boer J; van Amsterdam RG; Zaagsma J; Kelly JJ; Dent G J Pharmacol Exp Ther; 1995 Aug; 274(2):678-87. PubMed ID: 7636728 [TBL] [Abstract][Full Text] [Related]
62. Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction. Muller B; Lugnier C; Stoclet JC J Cardiovasc Pharmacol; 1990 Nov; 16(5):796-803. PubMed ID: 1703603 [TBL] [Abstract][Full Text] [Related]
63. Investigations of the mechanism of the positive inotropic action of BDF 9148: comparison with DPI 201-106 and the enantiomers. Raap A; Armah B; Mest HJ; Stenzel W; Schloos J; Blechacz W J Cardiovasc Pharmacol; 1997 Feb; 29(2):164-73. PubMed ID: 9057064 [TBL] [Abstract][Full Text] [Related]
64. Actions of the phosphodiesterase inhibitor zardaverine on guinea-pig ventricular muscle. Galvan M; Schudt C Naunyn Schmiedebergs Arch Pharmacol; 1990 Aug; 342(2):221-7. PubMed ID: 1700309 [TBL] [Abstract][Full Text] [Related]
65. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. Underwood DC; Kotzer CJ; Bochnowicz S; Osborn RR; Luttmann MA; Hay DW; Torphy TJ J Pharmacol Exp Ther; 1994 Jul; 270(1):250-9. PubMed ID: 8035322 [TBL] [Abstract][Full Text] [Related]
66. Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activity. Sircar I; Weishaar RE; Kobylarz D; Moos WH; Bristol JA J Med Chem; 1987 Nov; 30(11):1955-62. PubMed ID: 2822926 [TBL] [Abstract][Full Text] [Related]
67. Phosphodiesterase inhibition and positive inotropy in failing human myocardium. Schmitz W; Eschenhagen T; Mende U; Müller FU; Neumann J; Scholz H Basic Res Cardiol; 1992; 87 Suppl 1():65-71. PubMed ID: 1323266 [TBL] [Abstract][Full Text] [Related]
68. Mechanisms of the contractile effects of levosimendan in the mammalian heart. Bokník P; Neumann J; Kaspareit G; Schmitz W; Scholz H; Vahlensieck U; Zimmermann N J Pharmacol Exp Ther; 1997 Jan; 280(1):277-83. PubMed ID: 8996207 [TBL] [Abstract][Full Text] [Related]
69. New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors. Holubarsch C Cardiology; 1997; 88 Suppl 2():12-20. PubMed ID: 9142431 [TBL] [Abstract][Full Text] [Related]
70. Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics. Weishaar RE; Quade MM; Schenden JA; Evans DB J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(6):551-64. PubMed ID: 3003170 [TBL] [Abstract][Full Text] [Related]
71. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Pan X; Arauz E; Krzanowski JJ; Fitzpatrick DF; Polson JB Biochem Pharmacol; 1994 Aug; 48(4):827-35. PubMed ID: 7521642 [TBL] [Abstract][Full Text] [Related]
72. Positive inotropic and chronotropic effects of toborinone and its electrophysiological properties in the isolated hearts of rabbits and guinea-pigs. Takase H; Orito K; Mori T; Fujiki H; Sekiguchi K; Tominaga M; Iijima T Arzneimittelforschung; 1996 Jun; 46(6):579-86. PubMed ID: 8767347 [TBL] [Abstract][Full Text] [Related]
73. Does the positive inotropic action of a novel cardiotonic agent, MCI-154, involve mechanisms other than cyclic AMP? Kitada Y; Narimatsu A; Suzuki R; Endoh M; Taira N J Pharmacol Exp Ther; 1987 Nov; 243(2):639-45. PubMed ID: 2824754 [TBL] [Abstract][Full Text] [Related]
74. Studies on the mechanism of positive inotropic activity of Ro 13-6438, a structurally novel cardiotonic agent with vasodilating properties. Holck M; Thorens S; Muggli R; Eigenmann R J Cardiovasc Pharmacol; 1984; 6(3):520-30. PubMed ID: 6202981 [TBL] [Abstract][Full Text] [Related]
76. Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. Weishaar RE; Burrows SD; Kobylarz DC; Quade MM; Evans DB Biochem Pharmacol; 1986 Mar; 35(5):787-800. PubMed ID: 3006691 [TBL] [Abstract][Full Text] [Related]
77. In vitro characterization of the effects of MCI-154, a novel cardiotonic agent, on cardiac tissues. Narimatsu A; Kitada Y; Satoh N; Morita M; Muroyama A; Kobayashi M; Ohizumi Y Jpn J Pharmacol; 1989 Mar; 49(3):397-405. PubMed ID: 2545964 [TBL] [Abstract][Full Text] [Related]
79. An analysis of the mechanism of the inotropic action of some milrinone analogues in guinea-pig isolated atria. Dorigo P; Gaion RM; Belluco P; Mosti L; Borea PA; Maragno I Br J Pharmacol; 1991 Dec; 104(4):867-72. PubMed ID: 1810600 [TBL] [Abstract][Full Text] [Related]
80. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. Haikala H; Levijoki J; Lindén IB J Mol Cell Cardiol; 1995 Oct; 27(10):2155-65. PubMed ID: 8576932 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]